Dr Hal Barron – New Directorship

Summary by AI ^BETAClose X

GSK plc announced that Dr. Hal Barron, a Non-Executive Director, was appointed as an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on June 4, 2026. This appointment is being disclosed in accordance with UK Listing Rule 6.4.9R(2).

Disclaimer*

GSK PLC

09 June 2026

Issued: 9 June 2026, London UK

Dr Hal Barron - New Directorship

In accordance with UK Listing Rule 6.4.9R(2), GSK plc notes that Dr Hal Barron, a Non-Executive Director, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.

V A Whyte

Company Secretary

9 June 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END